|
|
|
|
Regulatory face-off or middle path?
The Chinese pharmaceutical market seems to be putting the ignominy of having to award capital punishment to the highest ranking official of the State Food and Drug Administration (SFDA) in July 2007 for corruption.With a revamp of the...
|
|
|
Investigator Portal: a new wave in translational research
There are several new IT enabled services being currently explored in the clinical research space to make operations seamless with a focus on high quality of data and regulatory compliance.Dr Ankasha Tejam and Dr Suguna Nandgaonkar...
|
|
|
Outsourced Adverse Event reporting - A channel for medical research
Software solutions that lower risks in drug discovery, while lowering costs in developmental cycles are proving a godsend for pharmaceutical companies.Sanjiv Kapur, Senior Vice President and Head - Patni BPO & CIS goes a step beyond...
|
|
|
Microbes An eternal source of innovative drugs
Refined fermentation process development strategies have geared up microbes as a sustained source of future drugs.Dr H Sivaramkrishna, President and Dr Girish Mahajan, Group Head, Anti-infective Screening & Prokaryote Isolation,...
|
|
|
Study identifies no side effects of rosiglitazone to cardiac diseases
Clinical trial results of the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) study, presented at the American Diabetes Association (ADA) meeting 2009, showed that overall rates of cardiovascular...
|
|
|
Rockwell executive wins 'Partner of the Year' award
The Control System Integrators Association (CSIA) honoured Mark Moriarty of Rockwell Automation as its 2009 'Partner of the Year' in recognition for his significant contributions and support of CSIA.Moriarty was recognised at CSIA's 16th...
|
|
|
Public health vs private enterprise
In the midst of the global slowdown, with but a few 'green shoots' of recovery struggling to break through, the Indian biotechnology fraternity will meet once more at Bangalore Bio, arguably India's biggest biotech event.On the agenda are...
|
|
|
Regulating biologics
The absence of regulatory guidance or clarity is often followed by chaos and misunderstanding.World over, the biopharmaceutical industry, in all its perplexity, is waiting for concrete rules to take over the mildly regulated biologics.
|
|
|
New faces in the making
GenX seems to be becoming a norm rather than the exception in the lifecsiences business.Serum Institute's Adar Poonawalla is the next young gun on the block. He cites the growth story of the company. A profile by Arshiya Khan Like...
|
|
|
Milken Institute Study reinforces PA's strength
The Milken Institute Study released at BIO 2009 reinforces Pennsylvania's strength and importance of the regional Life Science industry to the economy.Supriya K, Associate Director, Pennsylvania Trade & Investment Office- India give...
|
